Speaker Credentials
OMS-II
Speaker Credentials
BS
College
Dr. Kiran C. Patel College of Osteopathic Medicine, DO
Medical Specialty
Internal Medicine
Format
Poster
Start Date
November 2024
End Date
November 2024
Track
1
Abstract
Objective: To analyze the nephroprotective effects of SGLT-2 inhibitors, traditionally an antidiabetic medication, on the progression and outcomes of lupus nephritis (LN). Background: Systemic lupus erythematosus is a prevalent autoimmune condition resulting from the loss of tolerance against self-antigens. Widespread inflammation affects all body systems, especially the kidneys, resulting in lupus nephritis within 3 years. Lupus nephritis is a type 3 hypersensitivity that occurs due to immune complex deposition leading to inflammation of the nephrons that can progress to end-stage renal disease and renal failure if not treated effectively. Methods: A search was conducted using OVID, CINHAL, Web of Science, EMBAS, and Google Scholar. A total of 248 articles were analyzed, with 6 selected. Articles were considered eligible if they identified patients with lupus nephritis and analyzed the impact of SGLT-2 inhibitors. Results: Dapagliflozin at 10 mg was most commonly used among the patients. SGLT-2 inhibitors were found to reduce the risk of developing LN. All studies saw an improvement in the glomerular filtration rate. Further studies are required to fully analyze the impacts on proteinuria and albumin levels, as some indicated improvements while others noted consistent levels. Conclusion: Exploring SGLT-2 inhibitors as a therapeutic strategy for LN represents a promising and innovative approach to managing this complex condition. SGLT-2 inhibitors show potential benefits beyond glycemic control. Continued research and clinical trials will be pivotal in determining their definitive role in managing LN and improving patient outcomes.
Included in
The Use of Sodium-Glucose Transport Protein 2 Inhibitors in the Treatment of Lupus Nephritis: A Preliminary Systematic Review
Objective: To analyze the nephroprotective effects of SGLT-2 inhibitors, traditionally an antidiabetic medication, on the progression and outcomes of lupus nephritis (LN). Background: Systemic lupus erythematosus is a prevalent autoimmune condition resulting from the loss of tolerance against self-antigens. Widespread inflammation affects all body systems, especially the kidneys, resulting in lupus nephritis within 3 years. Lupus nephritis is a type 3 hypersensitivity that occurs due to immune complex deposition leading to inflammation of the nephrons that can progress to end-stage renal disease and renal failure if not treated effectively. Methods: A search was conducted using OVID, CINHAL, Web of Science, EMBAS, and Google Scholar. A total of 248 articles were analyzed, with 6 selected. Articles were considered eligible if they identified patients with lupus nephritis and analyzed the impact of SGLT-2 inhibitors. Results: Dapagliflozin at 10 mg was most commonly used among the patients. SGLT-2 inhibitors were found to reduce the risk of developing LN. All studies saw an improvement in the glomerular filtration rate. Further studies are required to fully analyze the impacts on proteinuria and albumin levels, as some indicated improvements while others noted consistent levels. Conclusion: Exploring SGLT-2 inhibitors as a therapeutic strategy for LN represents a promising and innovative approach to managing this complex condition. SGLT-2 inhibitors show potential benefits beyond glycemic control. Continued research and clinical trials will be pivotal in determining their definitive role in managing LN and improving patient outcomes.